Avoro Capital Advisors LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
Avoro Capital Advisors LLC disclosed 35 US equity positions worth $6.9bn in its Q3 2024 13F filing. The largest position was UTHR at 14.9% of the reported book, followed by ASND and ARGX.
What did Avoro Capital Advisors LLC own in Q3 2024? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP | Healthcare | 14.9% | $1.0bn | 2,858,888 | – | |
| 2 | ASND ASCENDIS PHARMA | Healthcare | 10.9% | $744.9m | 4,988,888 | – | |
| 3 | ARGX ARGENX SE | Healthcare | 9.8% | $671.3m | 1,238,467 | – | |
| 4 | KRYS KRYSTAL BIOTECH INC | Healthcare | 7.0% | $477.3m | 2,622,222 | – | |
| 5 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 6.3% | $430.6m | 2,029,000 | – | |
| 6 | APLSUSD APELLIS PHARMACEUTICALS INC. | 4.7% | $320.4m | 11,111,111 | – | ||
| 7 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 4.7% | $319.2m | 2,555,555 | – | |
| 8 | RNAGBP AVIDITY BIOSCIENCES INC | 4.6% | $315.8m | 6,875,000 | – | ||
| 9 | AM6 AMICUS THERAPEUTICS INC. | 3.6% | $247.5m | 23,175,000 | – | ||
| 10 | ITCIEUR INTRA-CELLULAR THERAPIES INC | 3.3% | $223.2m | 3,050,000 | – | ||
| 11 | XENE XENON PHARMACEUTICALS INC | Healthcare | 3.3% | $223.1m | 5,666,666 | – | |
| 12 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 3.1% | $213.0m | 4,500,000 | – | |
| 13 | VERA VERA THERAPEUTICS INC | Healthcare | 2.8% | $190.5m | 4,309,590 | – | |
| 14 | ARWR ARROWHEAD PHARMACEUTICALS INC. | Healthcare | 2.5% | $172.2m | 8,888,888 | – | |
| 15 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 2.1% | $143.3m | 2,038,015 | – | |
| 16 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 2.0% | $139.7m | 2,770,100 | – | |
| 17 | PCVX VAXCYTE INC | Healthcare | 2.0% | $134.3m | 1,175,000 | – | |
| 18 | SLNOEUR SOLENO THERAPEUTICS INC | 1.6% | $110.1m | 2,181,000 | – | ||
| 19 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 1.3% | $90.2m | 11,865,000 | – | |
| 20 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.1% | $74.9m | 3,888,437 | – | |
| 21 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.0% | $70.1m | 8,060,000 | – | |
| 22 | KURA KURA ONCOLOGY INC | Healthcare | 1.0% | $69.2m | 3,541,505 | – | |
| 23 | MERUS N V | 1.0% | $67.7m | 1,355,000 | – | ||
| 24 | TRML TOURMALINE BIO INC | 0.8% | $57.1m | 2,222,222 | – | ||
| 25 | MNKD MANNKIND CORP | Healthcare | 0.8% | $55.0m | 8,750,000 | – | |
| 26 | RARE ULTRAGENYX PHARMACEUTICAL INC | Healthcare | 0.7% | $46.1m | 830,000 | – | |
| 27 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 0.7% | $44.8m | 12,345,678 | – | |
| 28 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 0.6% | $39.8m | 4,240,000 | – | |
| 29 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 0.5% | $37.5m | 18,650,000 | – | |
| 30 | GLUE MONTE ROSA THERAPEUTICS INC | 0.4% | $30.7m | 5,790,236 | – | ||
| 31 | CGON CG ONCOLOGY INC | Healthcare | 0.4% | $26.4m | 700,000 | – | |
| 32 | DYN DYNE THERAPEUTICS INC. | Healthcare | 0.3% | $23.3m | 650,000 | – | |
| 33 | SYRE SPYRE THERAPEUTICS INC | 0.3% | $17.6m | 598,600 | – | ||
| 34 | WHWK AADI BIOSCIENCES INC | Healthcare | 0.1% | $5.9m | 2,849,402 | – | |
| 35 | NGNE NEUROGENE INC | 0.0% | $924.3k | 22,029 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.